Psoriatic arthritis (PsA) is a heterogeneous disease that can involve a variety 
of distinct anatomical sites including a patient's peripheral and axial joints, 
entheses, skin and nails. Appropriate management of PsA requires early 
diagnosis, monitoring of disease activity, and utilization of cutting edge 
therapies. To accomplish the former there are a variety of PsA-specific tools 
available to screen, diagnose, and assess patients. This review will outline the 
recently developed PsA screening tools, including the Toronto Psoriatic 
Arthritis Screening Questionnaire (TOPAS), the Psoriasis Epidemiology Screening 
Tool (PEST), the Psoriatic Arthritis Screening and Evaluation (PASE), and the 
Psoriasis and Arthritis Screening Questionnaire (PASQ). We will also review the 
Classification Criteria for Psoriatic Arthritis (CASPAR) and current PsA disease 
severity measures, such as the Disease Activity index for Psoriatic Arthritis 
(DAPSA), the Psoriatic Arthritis Joint Activity Index (PsAJAI) and the Composite 
Psoriatic Disease Activity Index (CPDAI). As is the case for PsA screening and 
assessment tools, there are also a variety of new therapies available for PsA. 
Historically, patients with PsA were treated with NSAIDS and traditional 
disease-modifying anti-rheumatic drugs (DMARDs). However, the ability of these 
medications to slow down the radiographic progression of joint disease has not 
been demonstrated. In contrast, anti-TNF agents, such as etanercept, infliximab, 
adalimumab, golimumab and certolizumab, are effective in this regard. Emerging 
PsA treatments include an oral phosphodiesterase 4 inhibitor, apremilast; a 
Janus kinase (JAK) inhibitor, tofacitinib; and several new biologics that target 
the IL-23/IL-17 pathway including secukinumab, brodalumab, ixekizumab, and 
ustekinumab. Herein we will review the mechanisms of action of these drugs, 
their results in clinical trials, and guidelines for administration. Lastly, 
treatment recommendations from the European League Against Rheumatism (EULAR) 
and The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 
(GRAPPA) will be discussed.